Verification evidence is still being completed.
PDF / print export
Light Chain Bioscience (Novimmune SA)
Plan-les-Ouates, Switzerland
- Verified lead
- Nicolas Fischer
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Bispecific Antibodies, Kappa-Lambda-Body Platform, and Multi-Specific Therapeutic Design
- Review cycle
- 24 April 2026
- Full address
- Plan-les-Ouates, Geneva, Switzerland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Light Chain Bioscience leadership team page confirming Nicolas Fischer as Chief Executive Officer.
- Editorial note
- Plan-les-Ouates bispecific antibody biotech with named CEO, kappa-lambda-body platform, and a history dating to 1998 as Novimmune SA.
Bispecific Antibodies, Kappa-Lambda-Body Platform, and Multi-Specific Therapeutic Design
Public CEO disclosure on leadership team page, Swiss Biotech Association listing, Long-standing biotech track record
Plan-les-Ouates bispecific antibody biotech with named CEO, kappa-lambda-body platform, and a history dating to 1998 as Novimmune SA.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Plan-les-Ouates, Switzerland
Light Chain Bioscience (Novimmune SA)
Bispecific Antibodies, Kappa-Lambda-Body Platform, and Multi-Specific Therapeutic Design · Bispecific antibody discovery and development
Plan-les-Ouates bispecific antibody biotech with named CEO, kappa-lambda-body platform, and a history dating to 1998 as Novimmune SA.
- Lead
- Nicolas Fischer (verified ↗)
- Address
- Plan-les-Ouates, Geneva, Switzerland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Bispecific antibody discovery and development
- Capabilities
- Kappa-Lambda-Body Bispecific Antibody Platform · Native-Human-Structure Antibody Design · Multi-Specific Oncology and Immunology Programs
- Founded
- 1998
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Nicolas Fischer
Chief Executive Officer
Full addressPlan-les-Ouates, Geneva, Switzerland
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
BioAlps organization listing for Light Chain Bioscience - NovImmune SA in Plan-les-Ouates.
Open sourceBispecific antibody discovery and development
Plan-les-Ouates, Switzerland. Bispecific Antibodies, Kappa-Lambda-Body Platform, and Multi-Specific Therapeutic Design. Review completed on 24 Apr 2026.
Swissmedic, EMA, and FDA for future clinical development
Public CEO disclosure on leadership team page, Swiss Biotech Association listing, Long-standing biotech track record
Bispecific Antibodies, Kappa-Lambda-Body Platform, and Multi-Specific Therapeutic Design
Plan-les-Ouates bispecific antibody biotech with named CEO, kappa-lambda-body platform, and a history dating to 1998 as Novimmune SA.
Editorial note
Light Chain Bioscience (a brand of Novimmune SA) is a Plan-les-Ouates biotech with a named CEO, a proprietary kappa-lambda-body platform for native bispecific antibodies, and a history dating to 1998.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Kappa-Lambda-Body Bispecific Antibody Platform
Native-Human-Structure Antibody Design
Multi-Specific Oncology and Immunology Programs
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Kappa-lambda-body discovery platform
Bispecific antibody engineering
Multi-specific therapeutic workflow
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Light Chain Bioscience (Novimmune SA) located?
- Light Chain Bioscience (Novimmune SA) operates from Plan-les-Ouates, Geneva, Switzerland, Plan-les-Ouates, Switzerland.
- Who runs Light Chain Bioscience (Novimmune SA)?
- Light Chain Bioscience (Novimmune SA) is led by Nicolas Fischer, Chief Executive Officer. Verified 24 Apr 2026.
- What does Light Chain Bioscience (Novimmune SA) do?
- Plan-les-Ouates bispecific antibody biotech with named CEO, kappa-lambda-body platform, and a history dating to 1998 as Novimmune SA. Core capabilities: Kappa-Lambda-Body Bispecific Antibody Platform, Native-Human-Structure Antibody Design, Multi-Specific Oncology and Immunology Programs.
Editorial context
Related technical briefs
Briefs that name Plan-les-Ouates as a covered market or city.